THT Biomaterials GmbH: Company Profile

Background

Overview

THT Biomaterials GmbH, established in 2020, is a privately-owned biotechnology startup based in Vienna, Austria. The company specializes in developing and commercializing human placenta-derived extracellular matrix (ECM) proteins, aiming to enhance the quality and ethical standards of tissue engineering and regenerative medicine.

Mission and Vision

The mission of THT Biomaterials is to address significant methodological challenges in drug development, tissue engineering, and regenerative medicine by replacing animal-derived components with human-derived materials. This approach seeks to improve the translational relevance of research and reduce ethical concerns associated with animal testing. The company's vision is to humanize tissue engineering by providing standardized human biomaterials that facilitate more accurate and ethical scientific outcomes.

Primary Area of Focus

THT Biomaterials focuses on the development of human placenta-derived ECM proteins, such as collagen-I, laminin-111, and human placenta substrate (hpS). These products are designed to replace animal-derived materials in cell culture applications, including 2D and 3D cell cultures, organ-on-a-chip models, and 3D bioprinting, thereby enhancing the physiological relevance of in vitro models.

Industry Significance

By providing human-derived biomaterials, THT Biomaterials contributes to the advancement of personalized medicine and the reduction of animal testing in scientific research. Their products support the Three Rs principle—Replace, Reduce, Refine—by offering ethical alternatives to animal-derived components in biomedical research.

Key Strategic Focus

Core Objectives

• Humanization of Cell Culture Models: Develop and supply human-derived ECM proteins to replace animal-derived materials, improving the relevance and ethical standards of in vitro models.

• Advancement of Personalized Medicine: Utilize human placenta-derived materials to create more accurate models for drug development and regenerative therapies, facilitating personalized treatment approaches.

Specific Areas of Specialization

• 2D and 3D Cell Culture: Providing human-derived ECM proteins for cell culture applications to enhance the physiological relevance of in vitro models.

• Organoid and Spheroid Cultures: Supporting the development of organoid and spheroid models using human-derived materials to better mimic human tissue environments.

• 3D Bioprinting: Supplying bioinks based on human-derived ECM proteins for 3D bioprinting applications in tissue engineering.

Key Technologies Utilized

• Extracellular Matrix (ECM) Isolation: Techniques for extracting and purifying ECM proteins from human placenta tissue.

• Standardization Processes: Methods to ensure the consistency and reproducibility of human-derived ECM products.

• Bioprinting Technologies: Utilization of 3D bioprinting techniques to create complex tissue structures using human-derived materials.

Primary Markets Targeted

• Academic and Research Institutions: Providing ethical and standardized human-derived materials for biomedical research.

• Biotechnology and Pharmaceutical Companies: Supplying human-derived ECM proteins for drug development and regenerative medicine applications.

• Regulatory Bodies: Collaborating to validate human-derived materials as ethical alternatives to animal testing.

Financials and Funding

As a privately held startup, THT Biomaterials GmbH has not publicly disclosed detailed financial information or specifics about funding rounds. The company has been recognized for its innovative approach, including being among the top three candidates for the MERCUR 2022 innovation prize in Austria.

Pipeline Development

THT Biomaterials is actively developing a range of human-derived ECM products, including:

• Human Placenta Collagen-I: Available in liquid and freeze-dried forms, suitable for various cell culture applications.

• Human Placenta Laminin-111: Offered as a liquid product for cell culture and tissue engineering.

• Human Placenta Substrate (hpS): A standardized ECM substrate for coating and 3D gel applications.

These products are designed to enhance the quality and ethical standards of tissue engineering and regenerative medicine research.

Technological Platform and Innovation

Proprietary Technologies

• Human Placenta-Derived ECM Proteins: Extraction and purification of collagen-I, laminin-111, and hpS from human placenta tissue.

• Standardization Protocols: Development of methods to ensure the consistency and reproducibility of human-derived ECM products.

Significant Scientific Methods

• Cell Culture Enhancement: Utilizing human-derived ECM proteins to improve cell adhesion, proliferation, and differentiation in vitro.

• 3D Bioprinting: Incorporating human-derived ECM proteins into bioinks for the fabrication of complex tissue structures.

Leadership Team

Johannes Hackethal: CEO and Founder of THT Biomaterials GmbH. With over 10 years of experience in tissue engineering and regenerative medicine, he completed his doctoral thesis at the University of Natural Resources and Life Sciences (BOKU) Vienna in 2018. Johannes has authored several publications and holds patents in the field.

Peter Goldmann: CTO and Co-Founder of THT Biomaterials GmbH. He has been instrumental in the company's technological development and strategic direction.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in tissue engineering and regenerative medicine, is experiencing significant growth. There is an increasing demand for ethical and human-relevant research models, driving the need for human-derived biomaterials.